First Turn Management, LLC
- SEC CIK
- 0001993440
- Latest filing
- Aug 14, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 31
- −2 vs. Q1 2026
- Portfolio value
- $934.7M
- +$39.6M (+4.4%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| RVMDRevolution Medicines, Inc. | COM | 415,307 | $77.8M | 8.3% | −53,069−11.3% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 489,889 | $65.3M | 7.0% | +24,020+5.2% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 218,415 | $53.5M | 5.7% | +29,643+15.7% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 954,360 | $48.4M | 5.2% | +330,521+53.0% | Added | History |
| BBIOBridgeBio Pharma, Inc. | COM | 633,364 | $47.2M | 5.0% | −62,354−9.0% | Reduced | History |
| ROIVRoivant Sciences Ltd. | SHS | 1,331,066 | $47.1M | 5.0% | +140,948+11.8% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 84,932 | $46.0M | 4.9% | −19,794−18.9% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 527,412 | $44.9M | 4.8% | +243,712+85.9% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 600,200 | $36.2M | 3.9% | −186,644−23.7% | Reduced | History |
| CELCCelcuity Inc. | COM | 329,101 | $34.4M | 3.7% | +118,523+56.3% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,670,000 | $30.7M | 3.3% | +758,663+83.2% | Added | History |
| INSMINSMED Inc | COM PAR $.01 | 263,851 | $28.1M | 3.0% | +15,376+6.2% | Added | History |
| QUREuniQure N.V. | SHS | 608,925 | $28.0M | 3.0% | −6,564−1.1% | Reduced | History |
| ASNDAscendis Pharma A/S | ORD SHS | 104,877 | $28.0M | 3.0% | +28,577+37.5% | Added | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 83,528 | $28.0M | 3.0% | +41,087+96.8% | Added | History |
| DNTHDianthus Therapeutics, Inc. | COM | 285,771 | $27.9M | 3.0% | +64,850+29.4% | Added | History |
| PCVXVaxcyte, Inc. | COM | 443,836 | $25.8M | 2.8% | +443,836 | New | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 218,051 | $25.5M | 2.7% | −182,413−45.6% | Reduced | History |
| PVLAPalvella Therapeutics, Inc. | COM | 156,450 | $23.9M | 2.6% | +8,357+5.6% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 602,281 | $23.3M | 2.5% | −345,058−36.4% | Reduced | History |
| ERASErasca, Inc. | COM | 1,221,721 | $22.4M | 2.4% | +354,082+40.8% | Added | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,017,284 | $21.8M | 2.3% | 00.0% | Unchanged | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 582,497 | $19.7M | 2.1% | +24,161+4.3% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 138,822 | $18.4M | 2.0% | −374,948−73.0% | Reduced | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 154,018 | $17.1M | 1.8% | +154,018 | New | History |
| INBXInhibrx Biosciences, Inc. | COM | 164,783 | $15.6M | 1.7% | +164,783 | New | History |
| SRRKScholar Rock Holding Corp | COM | 271,227 | $14.9M | 1.6% | −175,163−39.2% | Reduced | History |
| ORKAOruka Therapeutics, Inc. | COM | 155,343 | $14.8M | 1.6% | +155,343 | New | History |
| KYMRKymera Therapeutics, Inc. | COM | 102,533 | $11.8M | 1.3% | −152,139−59.7% | Reduced | History |
| SIONSionna Therapeutics, Inc. | COM | 110,493 | $4.86M | 0.5% | +110,493 | New | History |
| NUVLNuvalent, Inc. | COM | 26,298 | $3.25M | 0.3% | −344,046−92.9% | Reduced | History |
Sold out since Q1 2026 (7)
Positions held at the end of Q1 2026 that are gone from this filing.
| Security | Class | Shares in Q1 2026 | Value in Q1 2026 | % of portfolio in Q1 2026 | History |
|---|---|---|---|---|---|
| IDYAIDEAYA Biosciences, Inc. | COM | 873,838 | $29.1M | 3.3% | History |
| FULCFulcrum Therapeutics, Inc. | COM | 2,256,109 | $17.3M | 1.9% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 326,694 | $17.2M | 1.9% | History |
| VERAVera Therapeutics, Inc. | CL A | 422,023 | $17.0M | 1.9% | History |
| NTRANatera, Inc. | COM | 81,077 | $16.2M | 1.8% | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 768,662 | $11.5M | 1.3% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 315,563 | $5.88M | 0.7% | History |